ArticleMolecular pharmaceutics2014
In vivo tumor vasculature targeted PET/NIRF imaging with TRC105(Fab)-conjugated, dual-labeled mesoporous silica nanoparticles.
Article in Molecular pharmaceutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Meta-Analysis of Nanoparticle Delivery to Tumors Using a Physiologically Based Pharmacokinetic Modeling and Simulation Approach.ACS nano · 2020Pooled it
- TargetedJournal of nanobiotechnology · 2026Article
- Advances in immunoPET/SPECT imaging: The role of Fab and F(ab')Acta pharmaceutica Sinica. B · 2025Review
- Advancements in Micro/Nanorobots in Medicine: Design, Actuation, and Transformative Application.ACS omega · 2025Review
- Exploring innovative strides in radiolabeled nanoparticle progress for multimodality cancer imaging and theranostic applications.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Review
- Translocator Protein 18 kDa (TSPO): A Promising Molecular Target for Image-Guided Surgery of Solid Cancers.Advanced pharmaceutical bulletin · 2024Review
- Multimodal laparoscopic coincidence gamma imaging system for near-infrared fluorescence guided surgery: a preclinical study.Journal of medical imaging (Bellingham, Wash.) · 2023Article
- Nanomaterial-based contrast agents.Nature reviews. Methods primers · 2023Article
- Molecular Imaging and Nanotechnology-Emerging Tools in Diagnostics and Therapy.International journal of molecular sciences · 2022Review
- Endoglin in the Spotlight to Treat Cancer.International journal of molecular sciences · 2021Review
- The Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors.Chemical reviews · 2021Review
- Understanding the mechanisms of silica nanoparticles for nanomedicine.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2021Review
- Cross-Link-Functionalized Nanoparticles for Rapid Excretion in Nanotheranostic Applications.Angewandte Chemie (Weinheim an der Bergstrasse, Germany) · 2020Article
- Multimodal Decorations of Mesoporous Silica Nanoparticles for Improved Cancer Therapy.Pharmaceutics · 2020Review
- Particle-Size-Dependent Delivery of Antitumoral miRNA Using Targeted Mesoporous Silica Nanoparticles.Pharmaceutics · 2020Article
- Characterization and validation of multimodal annihilation-gamma/near-infrared/visible laparoscopic system.Journal of biomedical optics · 2019Article
- Multimodality Imaging Agents with PET as the Fundamental Pillar.Angewandte Chemie (International ed. in English) · 2019Review
- Theragnostic potentials of core/shell mesoporous silica nanostructures.Nanotheranostics · 2019Review
- Ultrasmall targeted nanoparticles with engineered antibody fragments for imaging detection of HER2-overexpressing breast cancer.Nature communications · 2018Article
- General synthesis of silica-based yolk/shell hybrid nanomaterials andNano research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Multifunctional mesoporous silica nanoparticles (MSN) with well-integrated multimodality imaging properties have generated increasing research interest in the past decade. However, limited progress has been made in developing MSN-based multimodality imaging agents to image tumors. We describe the successful conjugation of, copper-64 ((64)Cu, t1/2 = 12.7 h), 800CW (a near-infrared fluorescence [NIRF] dye), and TRC105 (a human/murine chimeric IgG1 monoclonal antibody) to the surface of MSN via well-developed surface engineering procedures, resulting in a dual-labeled MSN for in vivo targeted positron emission tomography (PET) imaging/NIRF imaging of the tumor vasculature. Pharmacokinetics and tumor targeting efficacy/specificity in 4T1 murine breast tumor-bearing mice were thoroughly investigated through various in vitro, in vivo, and ex vivo experiments. Dual-labeled MSN is an attractive candidate for future cancer theranostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.